For the latest updates on how we are managing changes due to COVID-19 please click here.

Ora Appoints David P. Bingaman, DVM, PhD, D. ACVO in Newly Created Chief Development Officer Position

BOSTON–(BUSINESS WIRE)–Ora, Inc., the world’s leading partner for ophthalmic pharmaceutical and device development, announced today that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role: Chief Development Officer (CDO).

Dr. Bingaman will oversee clinical and non-clinical activities that directly impact Ora’s customers around the world, ensuring that Ora’s broad range of capabilities and services delivers the high-quality outcomes for which Ora is known.

Ora’s clinical research spans all ophthalmic indications, where global teams focused on each subspecialty bring unparalleled operational insights and execution to the company’s customers. Ora’s concept-to-clinic services comprise ophthalmology-dedicated CMC and regulatory teams, as well as preclinical experts with deep translational science experience.

“For 45 years, innovators of ophthalmic products have relied upon Ora’s experienced people and our disciplined approach to innovating research methods and operational excellence,” said President, Chairman, and CEO, Stuart B. Abelson. “Dr. Bingaman’s background and leadership characteristics will ensure that Ora continues to consistently deliver outstanding development programs amidst increasing global demand for our knowledge, services, and technologies.”

“Ora’s breadth of knowledge and innovative spark are remarkable,” said Dr. Bingaman. “Their collaborative approach and can-do attitude make a transformational difference to client projects. I am honored to work with this incredibly accomplished team to continue to scale Ora’s great work for customers, partners, and patients around the world.”

Dr. Bingaman is a board-certified Veterinary Ophthalmologist with a PhD in Ocular Angiogenesis and deep roots in translational science. He also holds multiple patents and has authored numerous book chapters and peer-reviewed publications.

Throughout his career, Dr. Bingaman has established programs to study vision diseases with unmet medical needs, led clinical and non-clinical ophthalmic development strategies for early- and late-phase programs, and served as a collaborative, humble thought leader in the global ophthalmic space.

Before joining Ora, Dr. Bingaman served in large, public entities and small, privately held biotechnology companies. Prior employers include Alcon Laboratories, Alcon/Novartis, PanOptica, and, most recently, Oculis, where he held the role of Vice President and Head of Global Clinical Development.

About Ora, Inc.

Ora is the world’s leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world’s most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit, like us on Facebook, and follow us on LinkedIn

Ora® and Ora Logo are registered trademarks of Ora, Inc.